Cholangiocarcinoma+1
Not recruitingStudy on the Effectiveness and Safety of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab for Untreated HER2-Positive Biliary Tract Cancer Patients
Study on the Effectiveness and Safety of Gemcitabine, Cisplatin, Trastuzumab, and Pembrolizumab for Untreated HER2-Positive Biliary Tract Cancer Patients
- Disease:CholangiocarcinomaGallbladder cancer
- Substances:CisplatinPembrolizumab+2
Germany- Participants:18–64 years · 65+ years
- Substances:Cisplatin
- Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH











